Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Total Current Assets
All assets expected to be converted to cash or used up within one year.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 129.8% from a year ago
Total current assets stood at $730.16M at the end of Q1 FY2026, up 129.8% from a year earlier and up 107.9% from the prior quarter. Over 3 fiscal years it compounded at +72.5% a year.
Context
- Total current assets amounted to 97.7% of total assets at the end of Q1 FY2026, up 2.4 pp from a year earlier.
- Total current assets increased in 1 of the last 3 fiscal years.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +129.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 351.17M USD
- Year-over-year change
- -1.3%
- 3-year CAGR
- +72.5%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 351.17M | -1.3% |
| FY2024 | 2024-12-31 | 355.92M | +495.1% |
| FY2023 | 2023-12-31 | 59.8M | -12.6% |
| FY2022 | 2022-12-31 | 68.44M | — |
Total Current Assets vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's Mar 2026 total current assets of $730.16M is the 2nd highest of the 8 companies compared; the peer median is $228.27M.
- Its year-over-year change of +129.8% is the highest of 7, against a peer median of -6.8%.
- Total current assets amounts to 97.7% of total assets for ZBIO, versus a peer median of 89.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $760.05M | +32.5% | +32.9% | 99.9% | |
| Mar 2026 | $730.16M | +129.8% | +72.5% | 97.7% | |
UPBUpstream Bio, Inc. | Mar 2026 | $316.28M | -30.3% | +167.8% | 99.4% |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $289.4M | — | — | 99.6% |
| Mar 2026 | $228.27M | -14.9% | -0.8% | 86.8% | |
| Mar 2026 | $110.23M | +1.3% | -13.2% | 55.5% | |
| Mar 2026 | $57.2M | -16.7% | +5.5% | 89.8% | |
| Dec 2025 | $8.55M | +13.9% | -29.4% | 74.4% | |
| Peer median (excluding ZBIO) | $228.27M | -6.8% | +2.4% | 89.8% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.